3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide: A Next-Generation H+,K+-ATPase Inhibitor for Translational Gastric Acid Research

Introduction

The regulation of gastric acid secretion is central to understanding and treating gastric acid-related disorders, such as peptic ulcer disease and gastroesophageal reflux. At the molecular level, H+,K+-ATPase (the gastric proton pump) is the critical target for pharmaceutical intervention, as its inhibition directly attenuates acid secretion. Among the new generation of research tools, 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (SKU: A2845) has emerged as a potent and selective H+,K+-ATPase inhibitor, enabling advanced studies of the proton pump inhibition pathway and facilitating the design of translational models for antiulcer activity and gastric acid secretion research.

This article offers a comprehensive, mechanistic, and application-driven analysis of A2845, extending beyond existing scenario-based discussions and product overviews to provide a translational perspective. We critically examine its biochemical action, contrast its utility with alternative approaches, and contextualize its impact within the rapidly evolving landscape of gut–brain axis and neuroinflammation research—a field underscored by recent breakthroughs in imaging and microbiota studies (Kong et al., 2025).

Product Profile and Physicochemical Properties

3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (A2845), supplied by APExBIO at ~98% purity (HPLC and NMR verified), is a research-only compound specifically engineered for high specificity and reproducibility in antiulcer agent studies. Its molecular formula is C₁₇H₁₉N₃O₃S (molecular weight: 345.42), and it presents as a solid, insoluble in water and ethanol but highly soluble in DMSO (≥17.27 mg/mL). For optimal stability, storage at -20°C is recommended, with minimal solution storage advised. This stringent characterization ensures robust performance in both in vitro and in vivo models, a distinction critical for translational research workflows.

Mechanism of Action: Targeting the Proton Pump Inhibition Pathway

Biochemical Specificity and Inhibitory Potency

A2845 is a potent H+,K+-ATPase inhibitor with an IC₅₀ of 5.8 μM for direct enzyme inhibition and 0.16 μM for histamine-induced acid formation. Its mode of action involves binding to the catalytic domain of the proton pump, effectively blocking the final step of gastric acid secretion. This positions A2845 as a superior tool for dissecting the H+,K+-ATPase signaling pathway, facilitating granular analyses of downstream physiological effects in both acute and chronic models of gastric acid-related disorders.

This mechanistic precision distinguishes A2845 from first-generation inhibitors, enabling researchers to decouple primary and off-target effects during the study of peptic ulcer disease models or antiulcer activity. Notably, its high selectivity supports the generation of reproducible data, free from confounding secondary pharmacology.

Translational Relevance in Antiulcer Activity Studies

By tightly regulating proton pump activity, A2845 enables the creation of controlled models for chronic and acute gastric acid secretion, allowing for the precise evaluation of antiulcer agents and novel therapeutic interventions. This is particularly valuable for studies aiming to bridge the gap between cellular assays and whole-organism pathophysiology.

Comparative Analysis with Alternative Methods and Compounds

Previous content has highlighted the general efficacy and workflow reliability of A2845 in gastric acid secretion research scenarios (see scenario-based optimization). However, this article shifts focus to a comparative, translational framework—contrasting A2845 with classic proton pump inhibitors (PPIs) and alternative H+,K+-ATPase inhibitors.

• Classic PPIs (e.g., omeprazole): While widely used, these compounds often exhibit slower onset and broader off-target effects, complicating the interpretation of mechanistic studies. A2845's well-characterized IC₅₀ and specificity address these limitations, as discussed in the existing gold-standard tool review. Our analysis extends this perspective by emphasizing the compound's suitability for dissecting subtle signaling events in the H+,K+-ATPase pathway, where pharmacodynamic precision is paramount.
• Alternative H+,K+-ATPase Inhibitors: Many research-grade inhibitors lack the combination of high purity, proven stability, and robust solubility profile found in A2845, leading to experimental variability. APExBIO's stringent quality metrics directly address this reproducibility gap, supporting the rigorous demands of translational research.

In summary, while prior articles focus on practical laboratory scenarios or basic antiulcer modeling, this piece uniquely frames A2845 as an integrative tool for advanced, mechanism-driven studies that require both biochemical precision and translational flexibility.

Integrating 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide into Gut–Brain Axis and Neuroinflammation Models

Emerging Research: From Gastric Acid Secretion to Systemic Inflammation

Recent advances in neuroscience and gastroenterology highlight the bidirectional communication of the gut–brain axis, implicating gastric acid secretion and microbiota-derived metabolites in neuroinflammatory processes. Kong et al. (2025) demonstrated that modulating the gut microbiota, through approaches such as Bifidobacterium supplementation or fecal microbiota transplantation (FMT), impacts neuroinflammation in chronic hepatic encephalopathy models, as visualized by in vivo PET imaging of TSPO expression (read full study).

Although the referenced study focused on neuroinflammation and microbiota interventions, it underscores the importance of precisely manipulating the gastric environment—including acid secretion—for dissecting gut–brain–liver axis mechanisms. Here, A2845’s highly selective inhibition of the H+,K+-ATPase enables researchers to:

• Model acid-driven changes in gut microbiota composition and their impact on systemic inflammation.
• Pair antiulcer activity studies with neuroimaging endpoints, using tools such as [18F]PBR146 PET to monitor downstream neuroinflammatory responses.
• Build integrated preclinical models that connect gastric acid secretion research with behavioral and neurochemical outcomes.

Experimental Strategies and Protocol Considerations

Utilizing A2845 in conjunction with gut–brain axis models requires careful consideration of dosing, solubility, and pharmacokinetics. Its DMSO solubility and defined purity facilitate reproducible administration in both acute and chronic settings. Moreover, the compound's rapid onset and specificity allow for time-resolved studies, linking immediate gastric acid changes to downstream immunological or neurological events.

This approach extends and deepens the context set by recent reviews that briefly touch on the intersection of proton pump inhibition and gut–brain interactions (see prior mechanistic overview). In contrast, our article provides a practical translational roadmap, informed by recent imaging and behavioral studies, for integrating A2845 into complex experimental designs that probe the gut–liver–brain axis.

Advanced Applications: Beyond Standard Antiulcer Models

Modeling Gastric Acid-Related Disorders in the Context of Systemic Disease

Traditional antiulcer activity studies focus primarily on local gastric endpoints, such as mucosal healing or acid output. However, the evolving landscape of translational research necessitates tools that can bridge gastrointestinal physiology with systemic disease models—such as hepatic encephalopathy, metabolic syndrome, and neurodegenerative disorders—where gastric acid secretion plays a modulatory role.

A2845’s precision allows for:

• Dissecting the role of gastric acid in shaping gut microbiota composition and metabolite profiles, which can influence systemic inflammation and central nervous system function.
• Integrating antiulcer agent studies with multi-omics profiling (microbiome, metabolome, and transcriptome) to reveal novel signaling pathways.
• Combining pharmacological inhibition with advanced imaging (e.g., PET, MRI) to map the downstream effects of altered acid secretion on brain inflammation, as exemplified by the approach in Kong et al.

This advanced application focus is distinct from earlier articles that center on cytotoxicity assays or routine antiulcer screens (see cytotoxicity workflow discussion). Here, we emphasize the use of A2845 as a bridge between bench research and systemic disease modeling, offering opportunities for new discoveries at the intersection of gastroenterology, immunology, and neuroscience.

Best Practices for Use and Experimental Design

• Solubility: Dissolve in DMSO to a working concentration of ≥17.27 mg/mL. Avoid aqueous or ethanol solvents.
• Stability: Store as a solid at -20°C. Prepare fresh solutions for each experiment to maintain purity and potency.
• Dosing: Start with IC₅₀-relevant concentrations for enzymatic and cellular assays (5.8 μM for direct inhibition, 0.16 μM for histamine-induced models). Titrate as needed for in vivo protocols.
• Purity Verification: Leverage APExBIO’s batch-specific HPLC and NMR data to confirm consistency across studies.
• Controls: Incorporate classic PPIs and alternative H+,K+-ATPase inhibitors as controls to benchmark specificity and efficacy.

Conclusion and Future Outlook

3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (A2845) stands at the forefront of translational gastric acid secretion research. Its unparalleled specificity, purity, and physicochemical robustness empower researchers to move beyond classical antiulcer agent screens toward integrative models that illuminate the interplay between gastric physiology, gut microbiota, and systemic inflammation.

As the field advances, the strategic deployment of A2845 in conjunction with modern imaging techniques and multi-omics profiling will be critical for unraveling the complex crosstalk between the gut, liver, and brain. This compound not only enables high-precision antiulcer activity studies but also catalyzes discovery in emerging domains such as the gut–brain axis and neuroimmune modulation.

For researchers seeking to push the boundaries of gastric acid-related disorder research, the A2845 H+,K+-ATPase inhibitor from APExBIO is an essential, next-generation tool. Its integration into advanced experimental paradigms promises to accelerate both fundamental insights and translational breakthroughs in gastroenterology and beyond.